Published in F1000Res on April 19, 2016
Peripheral and spinal 5-HT receptors participate in cholestatic itch and antinociception induced by bile duct ligation in rats. Sci Rep (2016) 0.75
Macrophage Depletion Attenuates Extracellular Matrix Deposition and Ductular Reaction in a Mouse Model of Chronic Cholangiopathies. PLoS One (2016) 0.75
Clinical Applicability of Whole-Exome Sequencing Exemplified by a Study in Young Adults with the Advanced Cryptogenic Cholestatic Liver Diseases. Gastroenterol Res Pract (2017) 0.75
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab (2005) 9.14
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet (2014) 6.84
The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem (2003) 6.35
Primary biliary cirrhosis. Hepatology (2009) 5.35
Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev (2009) 5.11
Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell (2006) 4.64
Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov (2008) 4.43
Redundant pathways for negative feedback regulation of bile acid production. Dev Cell (2002) 3.51
Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology (2014) 3.29
Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med (2004) 3.17
FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science (2011) 3.16
Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A (2006) 3.05
Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med (2015) 2.86
Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology (2008) 2.79
Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology (2011) 2.67
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56
Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest (2003) 2.51
Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol (2012) 2.28
Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J Biol Chem (2003) 2.26
A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol (2009) 2.25
Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype. Hepatology (2014) 2.19
A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol (2002) 2.02
The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology (2011) 1.94
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem (2002) 1.85
Folding defects in P-type ATP 8B1 associated with hereditary cholestasis are ameliorated by 4-phenylbutyrate. Hepatology (2010) 1.76
Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology (2009) 1.72
Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology (2015) 1.65
A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci Transl Med (2014) 1.64
Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. J Hepatol (2015) 1.59
Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J Hepatol (2008) 1.56
24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology (2006) 1.54
Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4-phenylbutyrate. Hepatology (2015) 1.54
Bile acids: chemistry, physiology, and pathophysiology. World J Gastroenterol (2009) 1.51
Nuclear receptors in liver disease. Hepatology (2011) 1.34
Mutations in TJP2 cause progressive cholestatic liver disease. Nat Genet (2014) 1.32
FXR signaling in the enterohepatic system. Mol Cell Endocrinol (2012) 1.32
Bile formation and secretion. Compr Physiol (2013) 1.32
Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J Clin Gastroenterol (2005) 1.30
Regulation of cholesterol 7 alpha-hydroxylase mRNA and transcriptional activity by taurocholate and cholesterol in the chronic biliary diverted rat. J Biol Chem (1991) 1.28
Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. Nat Clin Pract Gastroenterol Hepatol (2006) 1.27
TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep (2012) 1.23
New molecular insights into the mechanisms of cholestasis. J Hepatol (2009) 1.23
Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol Metab (2014) 1.23
Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther (2005) 1.16
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol (2015) 1.12
Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. Gastroenterology (1986) 1.12
Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output. Hepatology (2011) 1.11
Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat Commun (2016) 1.05
Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology (2011) 1.05
Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem J (2003) 0.99
Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2. J Hepatol (2012) 0.99
Effects of cellular, chemical, and pharmacological chaperones on the rescue of a trafficking-defective mutant of the ATP-binding cassette transporter proteins ABCB1/ABCB4. J Biol Chem (2011) 0.97
Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol (2014) 0.95
Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology (2013) 0.95
Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Invest (2008) 0.92
Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4. J Lipid Res (2004) 0.90
Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol (2006) 0.89
Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. J Hepatol (2013) 0.88
Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice. Hepatology (2015) 0.88
Inhibition of intestinal bile acid transporter Slc10a2 improves triglyceride metabolism and normalizes elevated plasma glucose levels in mice. PLoS One (2012) 0.87
Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammation. Hepatology (2008) 0.84
The biliary HCO(3)(-) umbrella: experimental evidence revisited. Curr Opin Gastroenterol (2012) 0.84
Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease. Sci Rep (2015) 0.84
Genetic determinants of cholestasis. Clin Liver Dis (2013) 0.81
The critical role of myeloid-derived suppressor cells and FXR activation in immune-mediated liver injury. J Autoimmun (2014) 0.81
Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev (2011) 0.79
Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease. Expert Opin Investig Drugs (2015) 0.79
Targeting the FXR nuclear receptor to treat liver disease. Gastroenterology (2015) 0.78
Slc10a2-null mice uncover colon cancer-promoting actions of endogenous fecal bile acids. Carcinogenesis (2015) 0.78
Total biliary diversion as a treatment option for patients with progressive familial intrahepatic cholestasis and Alagille syndrome. J Pediatr Surg (2015) 0.76
Altered bile acid pool using IBAT inhibitors for constipation: a potentially increased risk of malignancy. Am J Gastroenterol (2012) 0.76
Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders. Dig Dis (2015) 0.76